ENXTPA:MEDCLPharmaceuticals
How Investors May Respond To MedinCell (ENXTPA:MEDCL) After EMA Accepts TEV-749 Schizophrenia Filing
Teva Pharmaceuticals International GmbH and MedinCell have announced that the European Medicines Agency has accepted their Marketing Authorization Application for TEV-749, a once-every-four-weeks subcutaneous olanzapine long-acting injectable for adult schizophrenia, supported by Phase 3 SOLARIS efficacy and safety data.
The filing showcases MedinCell’s SteadyTeq copolymer delivery technology in a major psychiatric indication, potentially broadening the clinical and commercial reach of its...